A study from Montefiore Einstein Comprehensive Cancer Center in Nature Neuroscience reveals that glioblastoma (GBM) is not just a local brain tumor but a systemic disease affecting the skull and immune system. GBM causes skull thinning, enlarging channels between the skull marrow and brain. This remodeling shifts immune balance—doubling pro-inflammatory neutrophils and nearly eliminating B cells—allowing pro-tumor cells to infiltrate the brain and fuel tumor aggressiveness.
Researchers also tested anti-osteoporosis drugs: zoledronic acid accelerated tumor progression, while denosumab blocked the effects of anti-PD-L1 immunotherapy. These findings highlight the tumor’s ability to manipulate the systemic immune environment and suggest that conventional bone-targeting therapies may have unintended consequences.
Overall, the study challenges the notion of GBM as a purely local disease and underscores the need for treatments that address its systemic effects on bone marrow and immune regulation.